uniQure N.V. (NASDAQ:QURE) Receives Average Recommendation of "Moderate Buy" from Analysts

Key Points

• uniQure N.V. has received a consensus rating of "Moderate Buy" from eleven brokerages, with an average 12-month price target of $37.82.
• Insiders have recently sold a total of 22,144 shares of uniQure stock, indicating a decrease in their ownership stake.
• uniQure reported earnings of ($0.82) per share for the last quarter, surpassing analysts' expectations, but fell short in revenue with $1.57 million against a forecast of $5.93 million.

Shares of uniQure N.V. (NASDAQ:QURE - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven research firms that are covering the stock, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $37.55.

Several brokerages recently commented on QURE. HC Wainwright reaffirmed a "buy" rating and set a $70.00 target price on shares of uniQure in a report on Thursday, May 29th. Cantor Fitzgerald raised shares of uniQure to a "strong-buy" rating in a report on Monday, May 19th. Chardan Capital reduced their target price on shares of uniQure from $38.00 to $35.00 and set a "buy" rating for the company in a report on Tuesday. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of uniQure in a report on Monday, May 12th. Finally, Wall Street Zen downgraded shares of uniQure from a "hold" rating to a "sell" rating in a report on Saturday, June 14th.

uniQure Stock Performance

Shares of QURE traded down $0.25 during midday trading on Monday, reaching $14.21. The stock had a trading volume of 199,820 shares, compared to its average volume of 1,422,210. The firm has a 50 day simple moving average of $14.89 and a 200-day simple moving average of $13.68. uniQure has a one year low of $4.45 and a one year high of $19.18. The firm has a market cap of $778.37 million, a PE ratio of -3.62 and a beta of 0.08. The company has a current ratio of 9.98, a quick ratio of 11.99 and a debt-to-equity ratio of 1.53.

uniQure (NASDAQ:QURE - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported ($0.69) EPS for the quarter, beating analysts' consensus estimates of ($0.89) by $0.20. The company had revenue of $5.26 million during the quarter, compared to the consensus estimate of $5.00 million. uniQure had a negative net margin of 1,387.98% and a negative return on equity of 1,010.74%. As a group, sell-side analysts anticipate that uniQure will post -3.75 EPS for the current year.

Insider Activity at uniQure

In related news, Director Robert Gut sold 3,336 shares of the company's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $14.45, for a total transaction of $48,205.20. Following the completion of the transaction, the director directly owned 56,879 shares in the company, valued at $821,901.55. This represents a 5.54% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David D. Meek sold 2,112 shares of the company's stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $14.45, for a total transaction of $30,518.40. Following the transaction, the director owned 34,190 shares of the company's stock, valued at approximately $494,045.50. This represents a 5.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 22,144 shares of company stock worth $322,426 in the last 90 days. Corporate insiders own 4.79% of the company's stock.

Hedge Funds Weigh In On uniQure

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Aberdeen Group plc increased its position in uniQure by 24.2% in the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company's stock valued at $38,345,000 after acquiring an additional 535,163 shares during the period. KLP Kapitalforvaltning AS bought a new stake in shares of uniQure during the second quarter valued at approximately $117,000. Woodline Partners LP increased its holdings in shares of uniQure by 25.0% during the first quarter. Woodline Partners LP now owns 175,806 shares of the biotechnology company's stock valued at $1,864,000 after acquiring an additional 35,175 shares in the last quarter. 683 Capital Management LLC increased its holdings in shares of uniQure by 1.6% during the first quarter. 683 Capital Management LLC now owns 1,550,000 shares of the biotechnology company's stock valued at $16,430,000 after acquiring an additional 25,000 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of uniQure by 58.4% during the first quarter. Vestal Point Capital LP now owns 4,792,572 shares of the biotechnology company's stock valued at $50,801,000 after acquiring an additional 1,767,572 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.